Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Chronic Myeloid Leukemia

August 8, 2017

Join Jerald P. Radich, MD and Cecilia Yeung, MD from Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance as they present their expertise on a range of cases pertaining to chronic myeloid leukemia (CML).

CML is defined by the presence of Philadelphia chromosome resulting from a reciprocal translocation [t(9;22] that gives rise to a BCR-ABL1 fusion gene. Tyrosine kinase inhibitor (TKI) therapy with small molecule inhibitors of BCR-ABL tyrosine kinase has significantly reduced the annual mortality rate among patients with chronic phase CML (CP-CML). The goal of TKI therapy is to achieve complete cytogenetic response (CCyR) within 12 months of TKI therapy and to prevent disease progression. In patients achieving CCyR, CML is now managed like a chronic disease, requiring long-term treatment and supportive care.

A better understanding of the safety and efficacy profile of TKIs, the importance of molecular monitoring, and the significance of response milestones is essential to provide optimal long-term care for patients with CP-CML. Patient education on adherence to TKI therapy and close monitoring of patient’s adherence are critical to achieving early response milestones. Clinicians need to have up-to-date information to appropriately select and monitor these patients.

Target Audience

This educational program is designed to meet the educational needs of oncologists, pathologists, nurses, pharmacists, case managers, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Select the appropriate first-line TKI therapy for patients with CP-CML based on the risk score, toxicity profile of TKI, and individual patient characteristics.
  • Review the toxicity profile of individual TKIs and identify the factors contributing to non-adherence to TKI.
  • Develop an optimal long-term treatment plan incorporating regular monitoring of molecular response and effective supportive care plan for the prevention and management of potential treatment-related side effects.
Additional information
Supporters: 

This activity is supported by educational grants from:

  • Astellas and Medivation, Inc., a Pfizer Company
  • AstraZeneca
  • Celgene Corporation
  • Gilead Sciences, Medical Affairs
  • Lilly
  • Novartis
  • Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc.
  • Taiho Oncology
  • Takeda Oncology

This activity is supported by independent educational grants from:

  • AbbVie
  • Boehringer Ingelheim Pharmaceuticals, Inc.

This educational activity is supported by a medical education grant from Exelixis, Inc.

Course summary
Available credit: 
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Course opens: 
08/07/2017
Course expires: 
10/01/2017
Event starts: 
08/08/2017 - 1:30pm EDT
Event ends: 
08/08/2017 - 2:30pm EDT
Cost:
$0.00
Part of: 
Monthly Oncology Tumor Boards (June 2017 - May 2018)
Add to calendar: 

Jerald P. Radich, MD
Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance

Cecilia Yeung, MD
Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance

 

Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

The faculty listed below disclose no relevant financial relationships:
Cecilia Yeung, MD

The faculty listed below discloses the following relevant financial relationships:
Jerald P. Radich, MD
ARIAD Pharmaceuticals, Inc.: Scientific Advisor
Gilead Sciences, Inc.: Scientific Advisor
Incyte Corporation: Scientific Advisor
Novartis Pharmaceuticals Corporation: Consulting Fees, Honoraria; Scientific Advisor; Grant/Research Support

The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Kim Bayer; Mark Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Joan S. McClure, MS; Diane McPherson; Melanie Moletzsky; Lisa Perfidio; Liz Rieder; Shannon K. Ryan; Kathy Smith; Melinda Somasekhar, PhD

The NCCN Clinical Information staff listed below, who has reviewed content, discloses no relevant financial relationships:
Hema Sundar, PhD

The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.

ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use.  Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.

Physicians
National Comprehensive Cancer Network is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

National Comprehensive Cancer Network designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 1.0 hour of Category I credit for completing this activity.

Nurses
National Comprehensive Cancer Network is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

NCCN designates this educational activity for a maximum of 1.0 contact hour.

Case Managers
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. The course is approved for 1.0 CE contact hour. Activity Code: I00027695; Approval Number: 170002702

Pharmacists

National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.1 CEUs) of continuing education credit. UAN: 0836-0000-17-076-L01-P

Available Credit

  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Reader or other PDF reader software for certificate viewing/printing